[A22-115] Ravulizumab (generalized myasthenia gravis) – Benefit assessment according to § 35a SGB V
Last updated 14.04.2023
Project no.:
A22-115
Commission:
Commission awarded on 21.10.2022 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis
- Adults who are still eligible for standard treatment: added benefit not proven
- Adults with refractory disease: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2023-02-01.
| Project no. | Title | Status |
|---|---|---|
| A21-125 | Ravulizumab (paroxysmal nocturnal haemoglobinuria) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-68 | Ravulizumab (atypical haemolytic uraemic syndrome) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-50 | Ravulizumab (neuromyelitis optica spectrum disorder [NMOSD]) – Benefit assessment according to §35a Social Code Book V | Commission completed |